Sugammadex and Time to Extubation in Ophthalmic Surgery

NCT06632067 | Completed

• 1 other identifier: CMUH112-REC3-124
• Study Type: observational
• Target: 262
• Locations: 1 country
• Sites: 1

Brief Summary

This study is to invastigate if patients treated with sugammadex compared to neostigmine/atropine would be extubate faster upon emergence of anesthesia.

Conditions

General Anesthesia Using Endotracheal Intubation; Ophthalmologic Surgical Procedure; Sugammadex; Neostigmine; Extubation Readiness

Keywords

sugammadex; general anesthesia; ophthalmologic surgical procedures

Outcome Measures

Primary Outcomes (2)

• Time From reversal to extubation

  Time From reversal to extubation

  Time From reversal to extubation

• Time From the end of surgery to reversal

  Time From the end of surgery to reversal

  Time From the end of surgery to reversal

Secondary Outcomes (1)

• Time From induction to the end of surgery

  Time From induction to the end of surgery

Study Arms (2)

sugammadex

those who use sugammadex for reversal of neuromuscular blockade

Drug: sugammadex

neostigmine

those who use neostigmine/atroping for reversal of neuromuscular blockade

Drug: Neostigmine + Atropine

Interventions

sugammadex DRUG

sugammadex used for neuromuscular reversal

sugammadex

Neostigmine + Atropine DRUG

Neostigmine and Atropine used for neuromuscular reversal

neostigmine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study included patients aged 18 years or older who underwent ophthalmic surgeries under general anesthesia with tracheal intubation between 2020 and 2022. Patients who received rocuronium as the sole neuromuscular blocking agent and were maintained with sevoflurane or desflurane and intravenous fentanyl were included. Based on the choice of reversal agent for neuromuscular blockade, patients were divided into two groups: the sugammadex group or the neostigmine group. Patients who underwent emergency surgery or combined surgeries with other specialties were excluded.

You may qualify if:

• aged 18 years or older ophthalmic surgeries under general anesthesia with tracheal intubation between 2020 and 2022 received rocuronium as the sole neuromuscular blocking agent maintained with sevoflurane or desflurane and intravenous fentanyl

You may not qualify if:

• emergency surgery combined surgeries with other specialties

Sponsors & Collaborators

• China Medical University Hospital: lead

Study Sites (1)

China Medical University Hospital

Taichung, 404327, Taiwan

Location

MeSH Terms

Interventions

Sugammadex; Neostigmine; Atropine

Intervention Hierarchy (Ancestors)

gamma-Cyclodextrins; Cyclodextrins; Macrocyclic Compounds; Polycyclic Compounds; Dextrins; Starch; Glucans; Polysaccharides; Carbohydrates; Phenylammonium Compounds; Quaternary Ammonium Compounds; Amines; Organic Chemicals; Onium Compounds; Atropine Derivatives; Tropanes; Azabicyclo Compounds; Aza Compounds; Belladonna Alkaloids; Solanaceous Alkaloids; Alkaloids; Heterocyclic Compounds; Bridged Bicyclo Compounds, Heterocyclic; Heterocyclic Compounds, Bridged-Ring

Study Officials

• Yi-Ying Chiang, MD

  China Medical Univerity Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 6, 2024
• First Posted: October 8, 2024
• Study Start: August 1, 2023
• Primary Completion: August 31, 2023
• Study Completion: August 31, 2023
• Last Updated: October 8, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)